A prospective randomized international study of 143 patients showed no apparent early
survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as …

The optimal dose of interferon-alfa (IFN) for chronic myeloid leukemia (CML) is unknown.
Retrospective analyses suggest that low doses are as effective as high doses, with less …

This multicenter randomized phase III study was designed to compare the efficacy and
toxicity of IFNα-2c (3.5 MU/d) in combination with either araC (10mg/m2 d1-10) or …

Background: Several randomized clinical trials in chronic myeloid leukemia (CML) have
reported better patient survival with interferon alfa (IFN α) than with standard …

In 1994, the Italian and the German Chronic myeloid leukemia (CML) trials comparing
interferon-alpha (IFN-alpha) with conventional chemotherapy were published. The survival …

During the last decade, several studies have evaluated the treatment of chronic phase
chronic myeloid leukemia (CML) with a combination of interferon (IFN)-α and low-dose …

The French Chronic Myeloid Leukemia Study Group prospective randomized study results
indicate that the addition of cytarabine to alpha interferon (IFN-α) increases the rate of major …

Compared to single-agent therapy with hydroxyurea or myleran (155 patients), intensive
chemo therapy with vincristine, cytosine arabinoside, prednisone and cyclophosphamide …

Ten years ago, alpha interferon (IFN-A) was introduced as a promising modality in the
management of patients with chronic myelogenous leukemia (CML). Since then, it has been …

Background Treatment with interferon prolongs survival in chronic myelogenous leukemia.
We conducted a clinical trial to assess the efficacy of treatment with a combination of …